Clinical trials: Botulinum Toxin, Type A
Glabellar Lines
Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines
This study will evaluate the safety and efficacy of two different types of botulinum toxin type A for the treatment of glabellar frown lines.
- Trial name
- NCT01271452
- Testing
- botulinum toxin type A
- Where
- Germany
- Volunteers
- 224 people
- Sponsor
- Allergan
COPD
A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPD
The aim of this clinical trial to determine the safety and effectiveness of treating the COPD symptoms with subcutaneous BOTOX injections in participants with moderate COPD.
- Trial name
- NCT06003049
- Testing
- OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- RMW Testing
Muscle Spasticity
Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity
This is a prospective, non-interventional, observational study to collect data on the use of botulinum toxin Type A in a routine setting in patients with upper limb adult spasticity.
- Trial name
- NCT01387074
- Testing
- botulinum toxin Type A
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- Allergan
Glabellar Lines
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)
The objective of this Phase 1 study is to assess the safety and efficacy of single treatment of AGN-151586 and of OnabotulinumtoxinA in the glabellar complex of participants with moderate to severe glabellar lines (GL).
- Trial name
- NCT06834789
- Testing
- AGN-151586, OnabotulinumtoxinA
- Where
- 8 sites in United States
- Volunteers
- 132 people
- Sponsor
- AbbVie
Glabellar Rhytides
A Long-Term Safety Study of Repeat Treatment With PurTox® for Frown Lines Between the Eyebrows
The overall purpose of this study is to evaluate the long-term safety of repeat treatment with an intramuscular dose of Mentor Purified Toxin for the reduction of frown lines.
- Trial name
- PT-03c (NCT00752258)
- Testing
- Mentor Purified Toxin Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 576 people
- Sponsor
- Mentor Worldwide, LLC
Urinary Incontinence, Overactive Bladder
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult…
- Trial name
- CONTENT1 (NCT02660138)
- Testing
- Botulinum toxin type A
- Where
- 81 sites in United States, Canada and 8 more
- Volunteers
- 227 people
- Sponsor
- Ipsen
Migraine Disorders
A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine
This study will evaluate the safety and efficacy of BOTOX® treatment in Korean adults with chronic migraine.
- Trial name
- NCT02147561
- Testing
- botulinum toxin Type A
- Where
- South Korea
- Volunteers
- 280 people
- Sponsor
- Allergan
Anal Fissure
Efficacy Study of Dysport® in the Treatment of Anal Fissure.
To evaluate the effect on healing rates of two different prognostic factors in patients treated with Dysport® for anal fissure: duration of fissure and dose of study drug
- Trial name
- NCT00210444
- Testing
- Botulinum toxin type A
- Where
- 7 sites in Czechia, Poland and 2 more
- Volunteers
- 168 people
- Sponsor
- Ipsen
Facial Contouring
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products
A study to evaluate overall participant satisfaction of face and neck appearance after treatment with onabotulinumtoxinA, JUVÉDERM® products, KYBELLA, CoolSculpting Elite, and select SkinMedica products in a diverse population.
- Trial name
- US Harmony (NCT06783621)
- Testing
- OnabotulinumtoxinA, JUVÉDERM, CoolSculpting Elite System
- Where
- 10 sites in United States
- Volunteers
- 130 people
- Sponsor
- AbbVie
Masseter Muscle Prominence
BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence
Based on the results of the Phase 2 Study 191622-130 [NCT02010775], the current Phase 2b study is designed to further evaluate the safety and efficacy of BOTOX® for the treatment of Masseter Muscle Prominence (MMP) in adults.
- Trial name
- NCT03861936
- Testing
- OnabotulinumtoxinA, Normal saline
- Where
- 14 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Allergan
Post Stroke Spasticity
Relation Between Dose and Time to Reinjection of Botulinum Toxin-A in Patient With Poststroke Spasticity From a Real-world Healthcare Insurance Database.
Determining the mean/median time between botulinum toxin-A injection within the treatment of patients with spasticity after stroke in relation to the botulinum toxin dose from a healthcare insurance database in the Netherlands.
- Trial name
- Relax (NCT04649632)
- Where
- Netherlands
- Volunteers
- 451 people
- Sponsor
- Ipsen
Stroke, Muscle Spasticity
Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function
The purpose of this study is to evaluate the safety of injections of botulinum toxin Type A in patients with reduced lung function and focal upper limb poststroke spasticity
- Conditions
- Stroke, Muscle Spasticity, Motor Neuron Disease
- Trial name
- NCT00076687
- Testing
- botulinum toxin Type A, saline
- Where
- 4 sites in United States, Czechia and 2 more
- Volunteers
- 155 people
- Sponsor
- Allergan
Blepharospasm
Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm
The purpose of this study is to evaluate the Efficacy and Safety of NABOTA in treatment of essential blepharospasm
- Trial name
- NCT02947815
- Testing
- Clostridium Botulinum Toxin Type A
- Where
- South Korea
- Volunteers
- 234 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Moderate to Severe Glabellar Lines
A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
This is a randomized, double-blind, placebo- and active-controlled parallel-group multi-center phase III study to evaluate the efficacy and safety of Rcombinant botulinum neurotoxin type A for injection (YY001)) in the treatment…
- Trial name
- NCT06499688
- Testing
- Rcombinant botulinum neurotoxin type A for injection (YY001), OnabotulinumtoxinA
- Where
- 16 sites in China
- Volunteers
- 529 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Glabellar Lines
The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines
A Phase I/Ⅱ Clinical Trial to Compare the Safety and Efficacy of HU-014 versus Botox® in Subject with Moderate to Severe Glabellar Lines
- Trial name
- NCT02961673
- Testing
- HU-014 Inj, Botox Inj
- Where
- South Korea
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Hyperhidrosis
A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis
This is a three year open-label study in subjects with axillary hyperhidrosis.
- Trial name
- NCT00168480
- Testing
- Botulinum Toxin Type A
- Where
- 4 sites in United States, Germany and 2 more
- Volunteers
- 424 people
- Sponsor
- Allergan
Cervical Dystonia
Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition in Patients With Change From Botulinum Toxin Type A
Investigation of the clinical condition in patients with cervical dystonia by Toronto Western Spasmodic Torticollis Scale (TWSTRS)
- Trial name
- NCT02175719
- Where
- 2 sites in Japan
- Volunteers
- 150 people
- Sponsor
- Eisai Co., Ltd.
Migraine Disorders
Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine
This study is an open-label extension study to evaluate the safety, tolerability and efficacy of BOTOX® as headache prophylaxis in Chinese patients with chronic migraine who have successfully completed the double-blind study…
- Trial name
- NCT03193359
- Testing
- botulinum toxin Type A
- Sponsor
- Allergan
Spasticity, Stroke
A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity
Purpose: This study is a Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb(wrist, finger…
- Trial name
- NCT01945684
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 197 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Moderate to Severe Glabellar Frown Lines
Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines
The purpose of the study is to investigate the safety and duration of effect following different doses of Botulinum Toxin A (NT 201) in the treatment of glabellar frown lines (GFL).
- Trial name
- NCT03806933
- Testing
- NT 201
- Where
- 9 sites in United States, Germany
- Volunteers
- 241 people
- Sponsor
- Merz Aesthetics GmbH